Adaptive designs undertaken in clinical research: A review of registered clinical trials

Trials

Volumn 17, Issue 1, 2016, Pages

  Hatfield, Isabella ^a,b   Allison, Annabel ^b,c   Flight, Laura ^b   Julious, Steven A ^b   Dimairo, Munyaradzi ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adaptive design; Clinical trial; Flexible design

Indexed keywords

CLINICAL RESEARCH; CONTROLLED CLINICAL TRIAL; DATA BASE; HUMAN; ONCOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); INFORMATION PROCESSING; METHODOLOGY; NOMENCLATURE; PROCEDURES; QUALITY CONTROL; REGISTER; STANDARDS;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; HUMANS; QUALITY CONTROL; REGISTRIES; RESEARCH DESIGN; TERMINOLOGY AS TOPIC;

EID: 84961201800     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1273-9     Document Type: Review

References (37)

1. Millard WB. The gold standard's flexible alloy: adaptive designs on the advance. Ann Emerg Med. 2012; 60(2):22-7.
2. Bauer P, Einfalt J. Application of adaptive designs - a review. Biom J. 2006; 48(4):493-506.
3. Coffey CS, Kairalla JA. Adaptive clinical trials. Drugs R&D. 2008; 9(4):229-42.
4. Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, et al.Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop. Clin Trials. 2012; 9(6):671-80.
5. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012; 13(1):145.
6. Gallo P, Anderson K, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, et al.Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. J Biopharm Stat. 2010; 20(6):1115-24.
7. Gaydos B, Anderson KM, Berry D, Burnham N, Chuang-Stein C, Dudinak J, et al.Good practices for adaptive clinical trials in pharmaceutical product development. Ther Innov Regul Sci. 2009; 43(5):539-56.
8. Quinlan J, Gaydos B, Maca J, Krams M. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials. 2010; 7(2):167-73.
9. Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006; 40(4):437-44.
10. Chuang-Stein C, Beltangady M. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective. J Biopharm Stat. 2010; 20(6):1143-9.
11. Cook T, DeMets DL. Review of draft FDA adaptive design guidance. J Biopharm Stat. 2010; 20(6):1132-42.
12. FDA Draft Guidance. Adaptive design clinical trials for drugs and biologics. Biotechnol Law Rep. 2010; 29(2):173.
13. Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, et al.Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials. 2014; 15(1):383.
14. Morgan CC, Huyck S, Jenkins M, Chen L, Bedding A, Coffey CS, et al.Adaptive design: results of 2012 survey on perception and use. Ther Innov Regul Sci. 2014; 48(4):473-81.
15. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011; 29(6):606-9.
16. Jaki T. Uptake of novel statistical methods for early-phase clinical studies in the UK public sector. Clin Trials. 2013; 10(2):344-6.
17. Dimairo M, Boote J, Julious SA, Nicholl JP, Todd S. Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials. 2015; 16(1):430.
18. ClinicalTrials.gov: a service of the US National Institutes of Health. https://clinicaltrials.gov/. Accessed May 2015.
19. World Health Organization. International clinical trials registry platform search portal. http://apps.who.int/trialsearch/. Accessed May 2014.
20. NIHR evaluation, trials and studies project portfolio. http://www.nets.nihr.ac.uk/projects?collection=netscc&meta_P_sand=Project. Accessed May 2015.
21. Chow SC, Chang M. Adaptive design methods in clinical trials. Boca Raton: CRC Press; 2011.
22. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. The Cochrane Library. 2009.
23. Lin M, Lee S, Zhen B, Scott J, Horne A, Solomon G, et al.CBER's experience with adaptive design clinical trials. Ther Innov Regul Sci. 2016; 50(2):195-203.
24. Stevely A, Dimairo M, Todd S, Julious SA, Nicholl J, Hind D, et al.An investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials: a methodological systematic review. PloS ONE. 2015; 10(11):0141104.
25. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994; 50(4):1029-41.
26. Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, et al.Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 2012; 13(1):168.
27. Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD, et al.Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials. 2009; 10(1):39.
28. James ND, Sydes MR, Mason MD, Clarke NW, Anderson J, Dearnaley DP, et al.Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol. 2012; 13(5):549-58.
29. Baraniuk S, Tilley BC, Del Junco DJ, Fox EE, van Belle G, Wade CE, et al.Pragmatic randomized optimal platelet and plasma ratios (PROPPR) trial: design, rationale and implementation. Injury. 2014; 45(9):1287-95.
30. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979; 35(3):549-56.
31. Lan KG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983; 70(3):659-63.
32. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al.Transfusion of plasma, platelets, and red blood cells in a 1: 1: 1 vs a 1: 1: 2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015; 313(5):471-82.
33. Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al.Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64(1):1-12.
34. Pritchett Y, Jemiai Y, Chang Y, Bhan I, Agarwal R, Zoccali C, et al.The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. Clin Trials. 2011; 8(2):165-74.
35. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al.Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012; 307(7):674-84.
36. Collinson FJ, Gregory WM, McCabe C, Howard H, Lowe C, Potrata B, et al.The STAR trial protocol: a randomised multi-stage phase II/III study of sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer. BMC Cancer. 2012; 12(1):598.
37. Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, et al.Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol. 2013; 31(36):4562-8.